



Eesti tervishoiu rahastamise võrdlus teiste riikidega ja efektiivsuse suurendamise võimalused


Mida teha tervisekassa tulevase puudujäägiga?

Veebiseminar, 22. veebruar, 2023


TOOMAS PALU, Maailmapank

Health Financing in Estonia: Known View

Health spending share of GDP, 2020 (%)





Share of total health financing, 2020 (%)






- Estonia is one of the lowest spenders in health in Europe
 - per capita spending
 - as share of GDP
- Share of private OOP spending is high
 - above 15% threshold when catastrophic impact wanes
- Share of general taxation in THE among lowest in EU
- One of 3 countries in EU+ without VHI


Health Financing in Estonia: Another View



- Estonia health financing has been resilient to shocks
- Public health spending has been growing at faster pace, catching up with EU average
- Growth of OOPs as share of THE is worrisome
- Estonia no longer a Bismarckian dinosaur



Determinants of Public Financing for Health*



*Tandon formula



$$\text{2000} \\ 11\% \times 36\% \times \text{US\$11,584} = \text{US\$455}$$

Revenues 36% + Deficit 0.1%

$$\text{2010} \\ 12\% \times 40\% \times \text{US\$16,988} = \text{US\$814}$$


Revenues 40% + Surplus 0.2%

$$\text{2020} \\ 13\% \times 45\% \times \text{US\$23,605} = \text{US\$1,378}$$


Revenues 39% + Deficit 6%

Size of economy matters, but so does overall revenue effort, willingness/ability to borrow, and priority to health

Composition of Health Expenditure Growth



- Estonia has among fastest growth rates of public expenditure on health
- Most from economic growth but reprioritization of health also important
- SHI the main driver but budget contribution also paying role



Footnotes:

- OECD data suggests that public expenditure growth rate accelerated further 2020-2021
- the best performer has relied completely on general budget allocation

Options for More Money for Health

- Change narrative – from health as recurrent discretionary spending to investment into human capital
- Resilient health system adds 1.4% of GDP on average health care costs in OECD countries compared to pre-pandemic normal
- Global trend to diversify away from SHI contributions as public revenue source for health
 - Cost of labor, gig economy, demographic changes impacting cost and revenues
 - Hard earmarking increasingly controversial
- Health taxes as an option for increasing Government revenues
 - Can contribute up to 2% of GDP (in Estonia currently around 1.2%)
 - Can be linked to soft earmarks for health
- Prioritizing health in budgets
 - Formula based allocations linked to costs for predictability and adequacy
- Reassess boundaries between private and public spending
- One silver bullet unlikely, combination of multiple measures
- Realize efficiency gains – **More Health for Money**

More Health for Money: Efficiency Gains

What Efficiency **IS**

Doing the right things...

...In the right places

...In the right way

What Efficiency is **NOT**

X Balancing revenues and expenditures

X Cutting budgets

These measures can actually reduce efficiency...



The 3 R's: a comprehensive, action-oriented approach to efficiency

Allocative efficiency

- public health, PHC, specialist and hospital care

Technical efficiency





- Review incentive framework – DRGs, value-based care
- Procurement efficiencies
- More targeted approaches for financial protection
- Secondary prevention, chronic disease management
 - Ambulatory Care Sensitive Conditions (ACSC)



| | Diabetes | Hypertension | Heart failure | COPD and Bronchiectasis | Asthma | Total (five conditions) |
|----------------------------|-----------|--------------|---------------|-------------------------|-----------|-------------------------|
| Admissions/discharges | 800 303 | 665 396 | 1 749 384 | 1 109 865 | 328 976 | 4 653 924 |
| % of all admissions | 1.0% | 0.8% | 2.1% | 1.3% | 0.4% | 5.6% |
| Average LOS (days) | 8.5 | 6.9 | 9.5 | 8.9 | 6.6 | 8.1 (avg.) |
| Total bed days | 6 794 572 | 4 597 886 | 16 619 148 | 9 855 601 | 2 177 821 | 37 603 706 |
| Proportion of all bed days | 1.1% | 0.7% | 2.7% | 1.6% | 0.4% | 6.5% |

EU countries, 2015. OECD, 2017



Disease Burden and ACSC



- Disease burden increases early in productive lives
- NCDs is a driver of health care costs
- Need to manage disease burden with efficiency and efficacy
 - Primary prevention
 - Secondary prevention and chronic case management
 - ASCS treatment cascade

Managing Disease Burden Better

Risk factors: age, excessive salt consumption, high saturated/trans fat diet, physical inactivity, low intake of fruits/vegetables, overweight/obesity, family history



Health promoting public policy

- Whole-of-government approach

- Health in All Policies

Secondary prevention and chronic case management

- Maximize performance of treatment cascade
- Minimize ACSCs in hospitals

Enablers

- Behavioral sciences
- Technology

Tänu!